Related Experiment Video

Updated: Jun 14, 2026

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

Effect of phlorizin on SGLT2 expression in the kidney of diabetic rats

Horacio Osorio1, Rocío Bautista, Amelia Rios

  • 1Department of Molecular Biomedicine, Center for Advanced Research and Study of the National Polytechnical Institute (CINVESTAV) Mexico City, Mexico.

Journal of Nephrology
|March 30, 2010
PubMed
Abstract

Insights

Increased kidney SGLT2 expression is linked to hypertension in diabetic rats. Phlorizin treatment, an SGLT2 inhibitor, reduced blood pressure and hyperglycemia, suggesting SGLT2 plays a role in diabetic hypertension.

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetes mellitus is associated with renal complications and hypertension.
  • Sodium-glucose cotransporter 2 (SGLT2) plays a role in glucose reabsorption in the kidneys.
  • Elevated SGLT2 expression in diabetic kidneys may contribute to hypertension.

Purpose of the Study:

  • To determine if increased kidney SGLT2 expression correlates with hypertension in diabetic rats.
  • To investigate the impact of phlorizin (P), an SGLT2 inhibitor, on blood pressure and SGLT2 expression in diabetic rats.

Main Methods:

  • Streptozotocin-induced diabetic rats were used, with groups receiving normal or high salt diets, and some treated with phlorizin.
  • Systolic blood pressure was monitored telemetrically over 30 days.
  • Renal function and SGLT2 expression in the renal cortex were assessed.

Main Results:

  • Diabetic rats exhibited hyperglycemia, glycosuria, diuresis, and increased systolic blood pressure and SGLT2 expression.
  • Phlorizin treatment in diabetic rats lowered blood glucose and prevented hypertension development.
  • Phlorizin decreased SGLT2 activity but did not alter SGLT2 expression levels.

Conclusions:

  • SGLT2 inhibition effectively prevented hypertension and hyperglycemia in diabetic rats.
  • These findings suggest a hypertensive mechanism linked to SGLT2 activity.
  • Increased SGLT2 expression may be associated with the progression of diabetic kidney disease.

More Related Videos

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Glucose Absorption Into the Small Intestine01:26

Glucose Absorption Into the Small Intestine

Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and 'exit' via the...